

Agios Pharmaceuticals, Inc. (AGIO)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001439222

Agios Pharmaceuticals, Inc.	
AGIO; healthcare	
Grade	B second fifth of 371 graded peers percentile 28.1; sampling error 2.5 points; lower is stronger
Rank	105 of 371
Profitability	D/E percentile 79.9
Solvency	A percentile 12.2
Growth and financing	B percentile 31.0
Reliability	0.91 AUC filers with \$591M to \$2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$591M to \$2.67B assets total assets \$1.3B
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	short runway not computable: fortress balance sheet
Inputs computable	8 of 14
Graded from	filings received through Feb 12, 2026 239 days before the rescans; latest periodic filing 10-Q received Jul 30, 2026
Last close	\$31.92 2026-10-08; market equity \$1.9B
Price used in grade	None

B, the elk
second fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescan
split-adjusted close; the letter is fixed at the rescan that set it

Rescans on file: B from Feb 21, 2026

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 12, 2026

. As of December 31, 2025, we had an accumulated deficit of \$561.7 million. We currently rely and expect to continue to rely on third parties for the manufacture of our product candidates for preclinical and clinical testing and for commercial supply of PYRUKYND® and AQVESME and any product candidate for which we may obtain marketing approval. Any performance failure on the part of our existing or future third-party manufacturers could delay clinical development, marketing approval or our

commercialization efforts.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 79.9						
Gross profitability		3.7%	32.2%	86.8	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(2.7%)	(6.6%)	73.0	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five consecutive annual gross margins are required
Solvency, sleeve percentile 12.2						
Twelve-month failure probability		0.03%	0.07%	16.6	248	2026-06-30
Altman Z double-prime		12.52	(0.31)	7.0	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		11.46x	2.96x	13.1	839	2025-12-31
Growth and financing, sleeve percentile 31.0						
Revenue growth, three-year compound		56.0%	10.0%	11.8	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			NOPAT must exceed \$100,000
Asset growth, three years		1.6%	2.1%	47.9	704	2025-12-31
Net share issuance, one year		2.3%	2.5%	33.2	634	2026-02-06


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 3.3 months

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
100	Lineage Cell Therapeutics, Inc. (LCTX)	26.8	B	
101	Traverse Therapeutics, Inc. (TVTX)	27.0	B	
102	Tela Bio, Inc. (TELA)	27.3	B	fortress
				balance sheet
103	Alphatec Holdings, Inc. (ATEC)	27.6	B	
104	Agape ATP Corp. (ATPC)	27.8	B	late filer
105	Agios Pharmaceuticals, Inc. (AGIO) <	28.1	B	short runway
106	Myriad Genetics Inc. (MYGN)	28.4	B	fortress
				balance sheet
107	DocGo Inc. (DCGO)	28.6	B	late filer,
				fortress
				balance sheet
108	Healthcare Services Group Inc. (HCSG)	28.9	B	
109	Staar Surgical Co. (STAA)	29.2	B	
110	Cytokinetics Inc. (CYTK)	29.5	B	short runway

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(16.1%)	8.0%	33
Distance from 52-week high	(29.8%)	(31.4%)	52
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(19.8%)	(1.0%)	23
Book value to price	0.54	0.28	72
Sales to price	0.03	0.31	10
Composite equity issuance, five years	(15.3%)	20.3%	10
Relative strength against the sector, log excess return	(0.39)	(0.14)	33

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$99.6M
Operating cash flow, four quarters	-\$360.6M

Months of runway	3.3
Days since last periodic filing	71 (10-Q received Jul 30, 2026)
Median daily dollar volume, 63 sessions	\$32.1M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$54.0M	2025-12-31	2026-02-12	10-K	0001439222-26-000025
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$6.3M	2025-12-31	2026-02-12	10-K	0001439222-26-000025
3	assets	us-gaap:Assets	\$1.3B	2025-12-31	2026-02-12	10-K	0001439222-26-000025
4	net income	us-gaap:NetIncomeLoss	-\$412.8M	2025-12-31	2026-02-12	10-K	0001439222-26-000025
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$373.0M	2025-12-31	2026-02-12	10-K	0001439222-26-000025
6	assets	us-gaap:Assets	\$1.7B	2024-12-31	2026-02-12	10-K	0001439222-26-000025
7	current assets	us-gaap:AssetsCurrent	\$942.1M	2025-12-31	2026-02-12	10-K	0001439222-26-000025
8	current liabilities	us-gaap:LiabilitiesCurrent	\$82.2M	2025-12-31	2026-02-12	10-K	0001439222-26-000025
9	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$561.7M	2025-12-31	2026-02-12	10-K	0001439222-26-000025
10	operating income	us-gaap:OperatingIncomeLoss	-\$472.1M	2025-12-31	2026-02-12	10-K	0001439222-26-000025
11	book equity	us-gaap:StockholdersEquity	\$1.2B	2025-12-31	2026-02-12	10-K	0001439222-26-000025
12	liabilities	us-gaap:Liabilities	\$104.1M	2025-12-31	2026-02-12	10-K	0001439222-26-000025
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$36.5M	2024-12-31	2026-02-12	10-K	0001439222-26-000025
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$26.8M	2023-12-31	2026-02-12	10-K	0001439222-26-000025
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$14.2M	2022-12-31	2025-02-13	10-K	0001439222-25-000009
16	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$4.3M	2025-12-31	2026-02-12	10-K	0001439222-26-000025
17	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$389.8M	2024-12-31	2026-02-12	10-K	0001439222-26-000025
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.7M	2024-12-31	2026-02-12	10-K	0001439222-26-000025
19	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$296.1M	2023-12-31	2026-02-12	10-K	0001439222-26-000025
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$999,000	2023-12-31	2026-02-12	10-K	0001439222-26-000025
21	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$309.5M	2022-12-31	2025-02-13	10-K	0001439222-25-000009
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$4.9M	2022-12-31	2025-02-13	10-K	0001439222-25-000009
23	depreciation amortization	us-gaap:Depreciation	\$5.2M	2025-12-31	2026-02-12	10-K	0001439222-26-000025
24	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$113.6M	2025-12-31	2026-02-12	10-K	0001439222-26-000025
25	income tax	us-gaap:IncomeTaxExpenseBenefit	-\$1.0M	2025-12-31	2026-02-12	10-K	0001439222-26-000025
26	current assets	us-gaap:AssetsCurrent	\$965.6M	2024-12-31	2026-02-12	10-K	0001439222-26-000025
27	current liabilities	us-gaap:LiabilitiesCurrent	\$81.2M	2024-12-31	2026-02-12	10-K	0001439222-26-000025
28	assets	us-gaap:Assets	\$937.1M	2023-12-31	2025-02-13	10-K	0001439222-25-000009
29	assets	us-gaap:Assets	\$1.2B	2022-12-31	2024-02-15	10-K	0001439222-24-000035
30	shares outstanding	dei:EntityCommonStockSharesOutstanding	58,592,172	2026-02-06	2026-02-12	10-K	0001439222-26-000025
31	shares outstanding	dei:EntityCommonStockSharesOutstanding	57,296,167	2025-02-07	2025-02-13	10-K	0001439222-25-000009